GENE ONLINE|News &
Opinion
Blog

2022-07-12| Trials & Approvals

Sanofi’s siRNA Therapy Reduces Bleeds in Hemophilia, Meets Primary Endpoint

by Joy Lin
Share To

Preventive treatment with fitusiran, a small interference RNA (siRNA) therapeutic, reduced bleeds by 61% in patients with hemophilia A or B, with or without inhibitor, who have previously received factor or bypassing agent (BPA) prophylaxis, said Sanofi. The results of the Phase 3 ATLAS-PPX study evaluating fitusiran met the primary endpoint. 

The data was presented at the International Society of Thrombosis and Haemostasis (ISTH) 2022 Congress. 

 

Reducing Bleeds by 61.1%

 

Key findings from the Phase 3 study showed that fitusiran prophylaxis resulted in an overall median annualized bleeding rate (ABR) of 0.0, compared to a median ABR of 4.4 with prior prophylaxis. This siRNA therapeutic significantly reduced estimated annual bleeding by 61.1% compared to factor or BPA prophylaxis. During the trial, 63.1% of patients treated with fitusiran experienced zero treated bleeds compared to. 16.9% with prior factor or BPA prophylaxis. 

The most common side effects of fitusiran treatment included increased alanine aminotransferase, nasopharyngitis, and upper respiratory tract infection. Thromboembolic events were reported in 2 patients (3.0%), which were consistent with previously identified risk of fitusiran.

Related article: Sanofi Launches Nonprofit Brand To Distribute Medicines to Low-Income Countries

 

Treating Hemophilia Comes With Challenges

 

Hemophilia is an inherited bleeding disorder caused by a deficiency in blood clotting factors, which leads to spontaneous and excessive bleeding. 

The disease is typically treated with replacement of the clotting factors, but the body’s immune system may generate inhibitors to the replacement therapy, creating complications. For people who have developed a high level of inhibitors, BPA prophylaxis is used to circumvent the need for the missing clotting factors and generate thrombin. In recent years, several therapeutic approaches show promise as complementary or alternative treatments for hemophilia. 

One of these approaches, siRNA, silences genes by binding to target mRNA, inducing its cleavage which results in degradation. Fitusiran targets the anti-clotting protein antithrombin. By lowering levels of antithrombin, the drug promotes thrombin generation to restore hemostasis (the body’s response to bleeding) and prevent bleeding. 

Fitusiran uses Alnylam’s ESC-GaINAc conjugate technology which enables subcutaneous dosing with increased potency and durability. It may have the potential to provide prophylactic treatment for people with hemophilia A or B, with or without inhibitors, with as few as six injections per year. 

However, the investigational drug has its share of challenges. Fitusiran ran into its first FDA clinical hold in 2017 after a patient died due to a blood clot during a Phase 2 study. The hold was resolved within the year, but a second hold followed in 2020 as Sanofi investigated new clotting complications resulting from fitusiran treatment. Sanofi has since switched to a lower dosing regimen for fitusiran, but has said regulatory filings may be delayed until 2024.

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Sanofi, GSK Secure European COVID-19 Booster Approval, AstraZeneca Withdraws U.S. Application
2022-11-10
Insilico Makes its Biggest AI Deal Ever with Sanofi for Potential $1.2 Billion
2022-11-09
Sanofi, miRecule To Develop Muscular Dystrophy Candidate In $400+ Million Partnership
2022-10-05
LATEST
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05
EMA Urges Pholcodine’s Removal from European Market Following Safety Study
2022-12-05
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
2022-12-04
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
2022-12-02
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!